Moderna and Merck Report Phase 3 Results for Cancer Vaccine Combination

Moderna and Merck's Phase 3 INTerpath-001 trial results show that their combination of the mRNA cancer vaccine intismeran autogene and Merck's Keytruda improved patient outcomes for resected stage IIB-IV melanoma, with a 42% reduction in the risk of death or tumor recurrence and a 38% reduction in cancer spread. The companies plan to file for regulatory approval in the U.S., aiming for a potential launch in 2027. Keytruda is already approved for 19 cancer types, and these results suggest the combination could enhance efficacy across additional cancers.